Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
ALPHARETTA, Ga., Sept. 20, 2016 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that Daniel H. White, Chief Executive Officer and President, will present at the 2016 Ladenburg Thalmann Healthcare Conference on Tuesday, September 27, 2016, at 10:30 a.m. EDT in at the Sofitel Hotel in New York, NY. Mr. White will provide a Clearside overview and business update.
The presentation will be webcast live and may be accessed by visiting Clearside’s website at http://ir.clearsidebio.com. A replay of the webcast will be available for 30 business days.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly-traded, late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye. Clearside has a portfolio of clinical and pre-clinical programs using drug administration through the suprachoroidal space to provide a route of access to treat diseases of the back-of-the-eye such as retinal vein occlusion (RVO), uveitis, neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Clearside is currently enrolling patients in a Phase 3 clinical trial (PEACHTREE) for the treatment of patients with macular edema associated with non-infectious uveitis and has initiated IND-enabling studies for the treatment of wet AMD. Visit www.clearsidebio.com for more information.
Contacts Company: Charles Deignan Chief Financial Officer 678-270-4005 [email protected] Investors: Matthew Beck The Trout Group 646-378-2933 [email protected]
